Abstract
To identify evidence gaps in the literature of the burden of illness and treatment of pemphigus vulgaris (PV) and pemphigus foliaceus (PF) to support the launch of efgartigimod to treat these rare diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have